4475 Executive Drive
Suite 200
San Diego, CA 92121
United States
858 794 9600
https://www.calidibio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 41
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Allan J. Camaisa | CEO & Chairman of the Board | 306.18k | N/D | 1961 |
Ms. Wendy Pizarro Campbell Esq. | Chief Administrative Officer, Chief Legal Officer, Chief Diversity Officer & Corporate Secretary | 295.4k | N/D | 1972 |
Dr. Boris Minev M.D., Ph.D. | President of Medical & Scientific Affairs and Interim Chief Medical Officer | 400.1k | N/D | 1964 |
Mr. Andrew C. Jackson | Chief Financial Officer | N/D | N/D | 1969 |
Dr. Amish Patel Ph.D. | Senior Vice President of Technical Operations | N/D | N/D | 1977 |
Mr. Stephen Thesing | Chief Business Officer | N/D | N/D | 1966 |
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
La calificación ISS Governance QuickScore de Calidi Biotherapeutics, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.